Locoregional Control With Radiotherapy of Breast Cancer Patients With MACrometastases Treated With MAstectomy (MACMA) - Trial NCT06378294
Access comprehensive clinical trial information for NCT06378294 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital A Coruña and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital A Coruña
Timeline & Enrollment
N/A
Apr 20, 2021
Dec 31, 2029
Primary Outcome
Disease-free survival,Axillary recurrence rate
Summary
Sentinel lymph node biopsy (SLNB) is the standard procedure to stage the axilla in clinically
 node-negative invasive breast cancer (IBC) patients undergoing upfront surgery.
 
 The ACOSOG-Z0011 and the AMAROS trial demonstrated that SLNB with or without radiotherapy
 provided equivalent local control and survival to axillary lymph node dissection (ALND) in
 early-stage breast cancer patients with 1 or 2 positive SLNs. However, the ACOSOG-Z0011 trial
 did not included patients treated with mastectomy, and the AMAROS trial only included 17% of
 mastectomy patients.
 
 The investigators conduct an observational cohort study of early stage breast cancer patients
 receiving upfront mastectomy with 1 or 2 macrometastases after SLNB. The study aim to
 demonstrate a 5-year disease-free survival of not less than 80% when ALND is omitted and
 replaced by axillary radiotherapy, and determine the axillary recurrence rate.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06378294
Non-Device Trial